US Capitol Capsule: Embracing The 'Megafund' Strategy: Rescuing Biopharma Investment
This article was originally published in Scrip
Even in light of the economic rebound in the U.S. in recent years, public and private investment in the biopharmaceutical industry has remained tempered – mostly due to investors' concerns about the time it takes to see a return on investment and the risky nature of drug development – although venture capital invested in biotechs in the past couple of years has significantly improved, particularly in 2015.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.